Abstract: A method for reconstructing dynamic contrast-enhanced (DCE) MR images includes receiving a plurality of continuous free-breathing DCE images, the plurality of images obtained with a contrast, sorting the images by identifying a respiratory phase associated with each of the continuous free-breathing DCE images, reconstructing the plurality continuous free-breathing DCE images into a 4D respiratory motion-resolved image, obtaining 3D deformable motion vector fields (MVFs), and utilizing a deep learning based motion transformation integrated forward-Fourier (DL-MOTIF) model and the 3D deformable MVFs to reconstruct the DCE MR images.
Abstract: Computational refocusing-assisted deep learning methods, apparatus, and systems are described. In certain pathology examples, a representative image is generated using a machine learning model trained with uniformly focused training images generated by a Fourier ptychographic digital refocusing procedure and abnormalities are automatedly identified and/or enumerated based on the representative image.
Type:
Grant
Filed:
February 25, 2022
Date of Patent:
January 14, 2025
Assignees:
California Institute of Technology, Washington University
Inventors:
Changhuei Yang, Cheng Shen, Richard J. Cote, Siddarth Rawal
Abstract: Among the various aspects of the present disclosure is the provision of a NXTAR-derived oligonucleotides and uses thereof. An aspect of the present disclosure provides for a method of (i) suppressing androgen receptor (AR) expression, (ii) suppressing androgen receptor splice variants (including AR-V7) expression, (iii) treating cancer (e.g., prostate, breast, testis, ovarian, endometrial and skin) (iv) treating skin related diseases, such as androgenetic alopecia and acne vulgaris in a subject comprising administering to the subject a NXTAR-derived oligonucleotide (oligo) (NXTAR is a lncRNA also known as LOC105373241).
Abstract: Catalysts and methods for transformation of glycerol and a carbon feedstock, such as CO2, a carbonate salt or a bicarbonate salt, are described herein. Homogeneous catalysts include compounds of formula M[NHC-R-linker]aLbXc, where M is a transition metal, NHC is an N-heterocyclic carbene ligand, R is an alkyl or aryl group, linker is a polar group, L is a neutral ligand, X is an anionic ligand, a ranges from 1-3, b ranges from 0-3, and c ranges from 0-3. Heterogeneous catalysts include a solid support with a catalytically active compound immobilized on the solid support, where the catalytically active compound has the formula M[NHC-R-linker]aLbXc where M is a transition metal, NHC is an N-heterocyclic carbene ligand, R is an alkyl or aryl group; linker is a polar group, L is a neutral ligand, X is an anionic ligand, a ranges from 1-3, b ranges from 0-3, and c ranges from 0-3.
Type:
Grant
Filed:
May 21, 2018
Date of Patent:
January 14, 2025
Assignee:
The George Washington University
Inventors:
Jacob Mark Heltzel, Matthew Thomas Finn, Adelina Mitkova Voutchkova, Arturo Azua
Abstract: Disclosed herein are methods for prognosing the risk of progression of a disease or disorder associated with inflammation, e.g., asthma, in a subject. Such methods include detecting levels of a fungal species comprising Malassezia globosa in the subject.
Type:
Application
Filed:
June 5, 2024
Publication date:
January 9, 2025
Applicants:
University of Connecticut, Washington University
Inventors:
Yanjiao Zhou, Hanshu Yuan, Avraham Beigelman, Leonard Bacharier
Abstract: A photonic Mach Zehnder Interferometer (MZI) has a first arm with a first photonic waveguide transmitting a first light having a first phase, a second arm with a second photonic waveguide transmitting a second light having a second phase, and a Transparent Conducting Oxide (TCO) based assembly. The TCO assembly is positioned about the first photonic waveguide of the first arm to modulate the first phase of the first light traveling in the first photonic waveguide.
Abstract: The present disclosure encompasses compositions and methods for the treatment of precancerous skin lesions. Compositions of the invention comprise a cytotoxic agent and a thymic stromal lymphopoietin (TSLP) inducer.
Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods for mapping transposon insertions. Applications can include mapping the locations of self-reporting transposons (SRTs) from thousands of single cells in parallel, while simultaneously measuring mRNA abundance from the same single cells; analyzing genome-associated protein (GAP) (e.g., transcription factor) binding/interactions in a small number of cells in bulk, without single cell resolution; lineage tracing; or as an improved readout for transposon mutagenesis screens.
Type:
Grant
Filed:
December 11, 2019
Date of Patent:
December 31, 2024
Assignee:
Washington University
Inventors:
Robi D. Mitra, Arnav Moudgil, Michael Nathaniel Wilkinson, Zongtai Qi
Abstract: Among the various aspects of the present disclosure is the provision of transgenic hookworm compositions and systems and methods of use thereof. The present teachings include compositions for a transgenic hookworm that treats a disease, condition, or indication. Also disclosed is a personal protective biosystem based on the transgenic hookworm, and methods to treat a disease, condition, or indication of a subject using transgenic hookworm compositions.
Abstract: Probiotic bacteria are genetically modified to produce and excrete enhanced levels of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Exemplary probiotic bacteria include Lactococcus lactis (L. lactis). The genetically modified probiotic bacteria can be prepared as an aqueous suspension and/or incorporated into food and nutraceuticals for oral administration to a subject. An oral formulation including the genetically modified probiotic bacteria can be used to treat inflammatory diseases and/or behavioral disorders caused by or associated with GABA-GABA signaling deficiency or by excess of excitatory neurotransmitters (such as glutamate). Inflammatory conditions that can be treated with the genetically modified probiotic bacteria include multiple sclerosis (MS) and irritable bowel disease (IBD).
Type:
Application
Filed:
January 26, 2022
Publication date:
December 26, 2024
Applicants:
Washington State University, Eastern Washington University
Inventors:
Jean-Baptiste O. Roullet, Javier Ochoa-Reparaz, Kenneth Michael Gibson, Andrea Castillo
Abstract: Among the various aspects of the present disclosure is the provision of MHC-independent T cell receptor (miTCR) compositions and methods of making and using the same.
Abstract: Among the various aspects of the present disclosure is the provision of targeting TPL2 kinase as a novel strategy to block oncogenic KRAS-driven signaling, detection of TPL2 mutations, and uses of TPL2 inhibiting agents alone or in combination with chemotherapy in subjects having TPL2- or RAS-associated cancer.
Abstract: Antigens of Toxoplasma gondii that provide specific and strong delayed type hypersensitivity (DTH) immune response, or which stimulate IFN-? secretion, are used for testing subjects for infection. Any skin testing format may be adapted for testing for the delayed type hypersensitivity, including a patch, a needle, or a prong. Presence of DTH indicates infection. Alternate methods of detecting a T cell response including monitoring IFN-? secretion may be used.
Type:
Grant
Filed:
September 8, 2023
Date of Patent:
December 24, 2024
Assignee:
Washington University
Inventors:
Laurence David Sibley, Kevin M. Brown, Qiuling Wang, Iti Saraav
Abstract: Disclosed herein is are methods for isolating mammalian cells under continuous flow conditions, enriching mammalian cells under continuous flow conditions, and enriching microorganisms under continuous flow conditions. The methods include providing and loading a plurality of mammalian cells or microorganisms into an acoustic separation device. The acoustic separation device includes: an inlet; an outlet; a channel coupled to the inlet and the outlet, wherein the channel defines a flow path between the inlet and the outlet; a standing acoustic wave generating device; and at least one pillar array comprising a plurality of pillars, wherein the at least one pillar array is situated within the flow path defined by the channel, wherein the at least one pillar array includes a first pillar array and a second pillar array, wherein the first pillar array is substantially parallel to the second pillar array, wherein the first pillar array and the second pillar array form an enrichment structure.
Type:
Grant
Filed:
April 5, 2021
Date of Patent:
December 24, 2024
Assignee:
Washington University
Inventors:
Mikhail Y. Berezin, John Mark Meacham, Michael Binkley
Abstract: A computing device for use in a system for mapping brain activity of a subject includes a processor. The processor is programmed to select a plurality of measurements of brain activity that is representative of at least one parameter of a brain of the subject during a resting state. Moreover, the processor is programmed to compare at least one data point from each of the measurements with a corresponding data point from a previously acquired data set from at least one other subject. The processor is also programmed to produce at least one map for each of the measurements based on the comparison of the resting state data point and the corresponding previously acquired data point. The processor may also be programmed to categorize the brain activity in a plurality of networks in the brain based on the map.
Type:
Grant
Filed:
February 13, 2023
Date of Patent:
December 24, 2024
Assignee:
Washington University
Inventors:
Eric Leuthardt, Nicholas Szrama, Carl Hacker, Tim Laumann, Maurizio Corbetta, Abraham Z. Snyder
Abstract: Compositions and methods for the treatment, prevention, or reversal of a brain disease or disorder characterized by accumulation of debris within a brain in a subject in need by administration of a therapeutically effective amount of a composition comprising a perivascular macrophage (PVM) stimulating compound are disclosed.
Abstract: Among the various aspects of the present disclosure is the provision of systems and methods for growing or culturing podocytes and uses thereof. In one aspect, a podocyte culture system including an ECM-patterned substrate is disclosed. The ECM-patterned substrate includes a compliant substrate. The compliant substrate includes a predetermined stiffness ranging from about 0.1 kPa to about 10 kPa. The ECM-patterned substrate further includes a plurality of patterned elements deposited over an exposed surface of the compliant substrate.
Abstract: The present disclosure provides methods to quantify VCP phosphorylation at specific amino acid residue to predict responsiveness of a subject having a cancer or tumor to a genotoxic treatment, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
Abstract: Among the various aspects of the present disclosure is the provision of methods and systems for detecting cell states in a biological sample. An aspect of the present disclosure provides for a method of determining cell type or cell states. In some embodiments, the method comprises providing or having been provided a sample comprising DNA or RNA and generating a methylation profile for the DNA or RNA in the sample or providing or having been provided a methylation profile of the DNA or RNA in the sample.
Type:
Application
Filed:
October 18, 2020
Publication date:
December 5, 2024
Applicants:
Washington University, The Board Of Trustees Of The Leland Stanford Junior University